GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (FRA:LGDN) » Definitions » Inventories, Finished Goods

Ligand Pharmaceuticals (FRA:LGDN) Inventories, Finished Goods : €0.0 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Ligand Pharmaceuticals Inventories, Finished Goods?


Ligand Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Ligand Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Inventories, Finished Goods Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ligand Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ligand Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Ligand Pharmaceuticals (FRA:LGDN) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals (FRA:LGDN) Headlines

No Headlines